A Clinical Study of KW-3357 in Patients With DIC
NCT01384396 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2017-03-24
Summary
To evaluate the efficacy and safety of KW-3357 with concomitant use of heparin using multi-center, non-comparative, open-label method in patients diagnosed as disseminated intravascular coagulation (DIC) by the diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare.
Conditions
- Disseminated Intravascular Coagulation (DIC)
Interventions
- DRUG
-
KW-3357
Intravenous infusion once a day
Sponsors & Collaborators
-
Kyowa Kirin Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-12-31
- Primary Completion
- 2013-04-30
- Completion
- 2013-04-30
Countries
- Japan
Study Locations
More Related Trials
-
Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
NCT01210755 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects
NCT02171455 ·Status: COMPLETED ·Phase: PHASE1
-
Apixaban in Thrombocytopenia
NCT06886516 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Reversal of the Antithrombotic Action of New Oral Anticoagulants
NCT01478282 ·Status: UNKNOWN ·Phase: PHASE4
-
Switching Study From Warfarin to Rivaroxaban
NCT01507051 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
NCT00005684 ·Status: COMPLETED
-
Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment
NCT01561937 ·Status: COMPLETED ·Phase: PHASE1
-
Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis
NCT04660747 ·Status: RECRUITING
-
Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis
NCT05705076 ·Status: UNKNOWN ·Phase: NA
-
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
NCT03269019 ·Status: UNKNOWN
-
Administration of Fibrinogen Concentrate for Refractory Bleeding
NCT05091684 ·Status: TERMINATED ·Phase: PHASE2
-
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
NCT02815670 ·Status: COMPLETED ·Phase: PHASE3
-
Medical Need of OAC Reversal
NCT03254147 ·Status: COMPLETED
-
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
NCT00558259 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluataion of NOAC Levels in Acute Stroke
NCT06144866 ·Status: RECRUITING
-
Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
NCT01083732 ·Status: COMPLETED ·Phase: PHASE2
-
Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
NCT05643651 ·Status: RECRUITING ·Phase: PHASE4
-
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
NCT01516840 ·Status: COMPLETED ·Phase: PHASE3
-
A Healthy Volunteer Study to Evaluate for a Single Dose of 4 Different Tablets of DPOC-4088 the Absorption and Elimination From the Body and the Potential Effect on Blood Clotting
NCT01347203 ·Status: COMPLETED ·Phase: PHASE1
-
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
NCT01516814 ·Status: COMPLETED ·Phase: PHASE3
-
Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis
NCT00506519 ·Status: TERMINATED ·Phase: PHASE2
-
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
NCT02104947 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States
NCT04565977 ·Status: COMPLETED
-
The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis
NCT03217448 ·Status: UNKNOWN ·Phase: PHASE3
-
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
NCT06575517 ·Status: WITHDRAWN